65,437 trials
Meibomian Gland Dysfunction · Blepharitis · Demodex Infestation
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 1; 1 Participants
Fathers
Primary: Parenting Behavior Measurement #1 — 4.23; 4.34 score on scale
SARS-CoV-2 Infection · COVID-19
Primary: Cohort 1: Percentage of Participants Reporting Local Reactions Within 7 Days After Study Vaccination — 5.8; 5.9; 3.8; 3.9 Percentage of participants
Dry Eye · Meibomian Gland Dysfunction
Primary: Change in Tear Break-Up Time (TBUT) From Baseline — 3.02; 2.58 Seconds
Sarcopenia
Primary: Change in 6MWT — 48.3 m
HIV-1-infection · Solid Organ Transplant
Primary: Change in Pharmacokinetic Parameters (Cmax, Cmin) of CsA Immunosuppressant — 825; 299; 86.5; 98.5 ng/mL
Cocaine Use Disorder
Primary: % Cocaine-Negative Urine Specimens Per Participant — 42.2; 59.1; 51.0 % negative specimens per participant — p=0.177
HIV Infections
Primary: Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 — 5.004; 4.923; 4.866; 4.636 log10 c/mL
Influenza, Human · SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants Who Reported Any Local Reaction up to 7 Days Following Vaccination — 56.3; 11.9; 59.0; 38.5 Percentage of participants
Hearing Loss, Sensorineural
Primary: Abbreviated Profile of Hearing Aid Benefit (APHAB) — 12.7; 13.18; 11.17; 12.22 score on a scale — p=0.38
Metastatic Solid Tumors
Primary: Percentage of Participants Experiencing Any Adverse Events — 66.7; 100.0; 91.7 percentage of participants
Hemophilia A
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 2; 2; 5 Participants
Anterior Cruciate Ligament Tear · Knee Meniscus Tear
Primary: Change in Quadriceps Strength Related to the Nerve Block — -0.42; -0.55; -3.19; -0.77 Newtons
Deep Vein Thrombosis · Pulmonary Embolism · Venous Thromboembolism
Primary: Frequency of Symptomatic, Recurrent VTE Defined as the Composite of Deep Vein Thrombosis and/or Pulmonary Embolism — 4; 30 Participants
Post-stroke Depression
Primary: Visual Analogue Scale (VAS) - Mood — 3.53; 5.23 Scores on a scale